Brief Reports
Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty

https://doi.org/10.1016/S0002-9149(99)00421-XGet rights and content

First page preview

First page preview
Click to open first page preview

References (7)

There are more references available in the full text version of this article.

Cited by (26)

  • Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction

    2006, Journal of the American College of Cardiology
    Citation Excerpt :

    The lower CKpeakin elderly patients and in those with prior MI might be explained by reduction of myocardial mass and, in diabetic patients, by lower myocardial expression of CK (26,27). Of note, abciximab use and stenting were not correlates of CKpeakin the CADILLAC trial, consistent with previous smaller studies (28,29). This observation is also consistent with the prior reported absence of a relationship between these modalities and recovery of left ventricular function (30).

  • Abciximab therapy improves 1-month survival rate in unselected patients with acute myocardial infarction undergoing routine infarct artery stent implantation

    2002, American Heart Journal
    Citation Excerpt :

    Moreover, the abciximab group had a better outcome despite higher peak CK values, which may be related to larger infarcts, and time to peak CK values were similar in the 2 groups. The last figures do not support the hypothesis of a faster release of CK from the infarcted tissue in the abciximab-treated group, which might be considered a marker of more effective reperfusion.11 However, it is not possible to rule out that the higher peak CK level in the abciximab-treated group was related to a more effective reperfusion, despite similar time to peak CK values in the 2 groups.

  • Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 trial

    2001, American Heart Journal
    Citation Excerpt :

    Several recent reports have addressed the effect of abciximab on reperfusion after primary PCI for acute myocardial infarction.24,25 These studies suggest that treatment with abciximab results in a more rapid early washout of cardiac enzymes24 and an improvement in the recovery of microvascular function over a 2-week period.25 Our study differs in that it uses a very early measurement of tissue level reperfusion and considers the situation of PCI as an adjunct to thrombolysis rather than as primary therapy for acute myocardial infarction.

  • Emergency management of acute coronary syndromes

    2000, Journal of Emergency Nursing
View all citing articles on Scopus
View full text